Patient Services in Action: Alicia Wolf As the social worker for ophthalmology services, Alicia Wolf has been assisting our providers in connecting their patients to resources to cope with low vision, as …
Age-related Macular Degeneration
TALON
A 64-Week, Two-Arm, Randomized, Double-Masked, Multi-Center, Phase IIIb Study Assessing the Efficacy and Safety of Brolucizumab 6 mg Compared to Aflibercept 2 mg in a Treat-To-Control Regimen in Patients with Neovascular Age-Related Macular Degeneration (TALON)
PULSAR
Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of High Dose Aflibercept in Patients with Neovascular Age-Related Macular Degeneration (PULSAR)
7 Ways to Protect Your Eyes from Age-Related Macular Degeneration
Age-related macular degeneration (AMD) is one of the leading causes of blindness over age 50, affecting about 2.1 million people nationwide. Early diagnosis and treatment are the keys to preventing vision loss. AMD is a …
IONIS-FB-LRx
The purpose of the study is to evaluate the effect of IONIS-FB-LRx on the rate of change of the area of geographic atrophy (GA) secondary to age-related macular degeneration (AMD) measured by fundus autofluorescence (FAF)
DERBY/GALE
A Phase III, Multi-Center, Randomized, Double-Masked, Sham Controlled Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy with Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) (DERBY)
GALLEGO/GALLEGOLE
A Phase II, Multicenter, Randomized, Single-Masked, Sham-Controlled Study to Assess Safety, Tolerability, and Efficacy of Intravitreal Injections of FHTR2163 in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration (GALLEGO)
OAKS/GALE
A Phase III, Multi-Center, Randomized, Double-Masked, Sham Controlled Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy with Sham Injections in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) (OAKS)
Most Americans Unaware of One of the Leading Causes of Blindness Among Seniors
Age-Related Macular Degeneration is one of the leading causes of blindness among seniors, affecting approximately 2.1 million people nationwide[1]. By 2050, it is expected that the number will more than double to 5.4 million[2]. People …